scholarly journals Should Pre-Transplant Hemoglobin A1c Be Used to Predict Post-Transplant Compliance in End-Stage Renal Disease Patients Undergoing Kidney Transplantation?

2020 ◽  
Vol 25 ◽  
Author(s):  
Samantha L. Terranella ◽  
Jennifer Poirier ◽  
Edie Y. Chan ◽  
Martin Hertl ◽  
Oyedolamu K. Olaitan
2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Umesh Lingaraj ◽  
Ricken Mehta ◽  
Shivaprasad SM ◽  
Kishan A ◽  
Leelavathi V ◽  
...  

Abstract Background and Aims Glomerulonephritis (GN) is a major cause of end stage renal disease (ESRD)1. It represents the primary cause of end stage renal disease (ESRD) for 25% of the dialysis population1 and 45% of the transplant population. For patients with GN requiring renal replacement therapy, kidney transplantation is associated with superior outcomes compared with dialysis2. The possibility of recurrence of the original disease after transplantation was described in a seminal paper more than 40 years ago, and it is now clear that all forms of GN may recur after kidney transplantation.3 To study the recurrence of glomerulonephritis post-transplant in a tertiary care centre. Method 120 renal transplant recipients were analyzed from September 2015 to August 2019 at the Institute of Nephro-Urology, Bangalore. It was a retrospective analysis of data Results 120 adult patients underwent kidney transplantation, out of these 70 had GN as primary cause of kidney disease. 85.8% were males, 14.2 % females. 58.9 % were biopsy proven GN, remaining 41.1 % diagnosed based on history and clinical presentation. All but one patient had their first transplant. Out of these kidney transplant recipients 08 (11.4%) had recurrence of GN.  From these 4/08 was recurrent IgA N, 2/08 were PGNMID, 1/08 MGN, 1/08 aHUS. Graft loss due to recurrent GN was seen in 1/08 patients (12.5%). Conclusion Our study showed that 11.4 % of kidney transplant recipients with GN as their cause of ESRD had recurrent GN post kidney transplantation. IgAN was the most type of GN that recurred most frequently followed by PGNMID. Recurrence of GN was in par with other studies and did not affect graft survival


2014 ◽  
Vol 28 (3) ◽  
pp. 299-306 ◽  
Author(s):  
Anna Paola Mitterhofer ◽  
Francesca Tinti ◽  
Valeria Pietropaolo ◽  
Ilaria Umbro ◽  
Elena Anzivino ◽  
...  

2014 ◽  
Vol 37 (6) ◽  
pp. 1075-1079 ◽  
Author(s):  
Yosuke Suzuki ◽  
Fumihiko Katagiri ◽  
Fuminori Sato ◽  
Kanako Fujioka ◽  
Yukie Sato ◽  
...  

Immunology ◽  
2018 ◽  
Vol 155 (2) ◽  
pp. 211-224 ◽  
Author(s):  
Matthias Schaier ◽  
Angele Leick ◽  
Lorenz Uhlmann ◽  
Florian Kälble ◽  
Christian Morath ◽  
...  

2001 ◽  
Vol 11 (3) ◽  
pp. 188-193 ◽  
Author(s):  
Zoltán Kaló ◽  
Jeno Járay ◽  
Júlia Nagy

Background— Kidney transplantation is generally acknowledged as the more clinically effective and more cost-effective option in managing patients with end-stage renal disease, compared with dialysis. This study looked for confirmatory evidence in a Hungarian population. Methods— Patients (n = 242) with end-stage renal disease who received cadaveric kidney transplantation during 1994 were followed up for 3 years. They were compared with patients (n = 840) receiving hemodialysis who were on a waiting list for transplantation. Data were collected retrospectively. Treatments were compared for clinical efficacy and for cost-effectiveness. Results— At month 36, the standard mortality hazard function was 3.5 times higher in the group receiving hemodialysis ( P<.0001) than in the transplant recipients. Average treatment costs per patient over the 3 years were also significantly higher ( P<.0001) in the hemodialysis group than in the group that received transplants. The cost of 1 year gained by transplantation was significantly less ( P<.0001) than the cost associated with hemodialysis. Conclusions— Compared with hemodialysis, kidney transplantation provides greater survival benefits to patients with end-stage renal disease, at less cost.


Sign in / Sign up

Export Citation Format

Share Document